Title of article :
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates
Author/Authors :
Jean-Yves Winum، نويسنده , , Silvia Pastorekova، نويسنده , , Lydia Jakubickova، نويسنده , , Jean-Louis Montero، نويسنده , , Andrea Scozzafava، نويسنده , , Jaromir Pastorek، نويسنده , , Daniela Vullo، نويسنده , , Alessio Innocenti، نويسنده , , Claudiu T. Supuran، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2005
Abstract :
A series of bis-sulfamates incorporating aliphatic, aromatic, or betulinyl moieties in their molecules was obtained by reaction of the corresponding diols/diphenols with sulfamoyl chloride. The library of bis-sulfamates thus obtained was tested for the inhibition of three physiologically relevant human carbonic anhydrase (hCA, EC 4.2.1.1) isozymes, the cytosolic hCA I and II, and the transmembrane, tumor-associated hCA IX. The new compounds reported here inhibited hCA I with KI s in the range of 79 nM–16.45 μM, hCA II with KI s in the range of 6–643 nM, and hCA IX with KI s in the range of 4–5400 nM. Several low nanomolar hCA IX inhibitors were detected, such as 1,8-octylene-bis-sulfamate or 1,10-decylene-bis-sulfamate (KI s in the range of 4–7 nM), which showed good selectivity ratios (in the range of 3.50–3.85) for hCA IX over hCA II inhibition. The most selective hCA IX inhibitor was phenyl-1,4-dimethylene-bis-sulfamate (KI of 61.6 nM), which was a 10.43 times better hCA IX than hCA II inhibitor. These derivatives are interesting candidates for the development of novel antitumor therapies targeting hypoxic tumors, since hCA IX is highly overexpressed in such tissues, and its presence is correlated with bad prognosis and unfavorable clinical outcome.
Journal title :
Bioorganic & Medicinal Chemistry Letters
Journal title :
Bioorganic & Medicinal Chemistry Letters